Skip to content

United Therapeutics

US · UTHR #836 by market cap Listed 1970
554.73 -4.37 -0.78%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 561.38 +0.41%
After-hours 550.23 -0.81%
608.49472.21554.732026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on UTHR?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +11.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 4.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall A
ValuationGrowthProfitMomentumHealthAnalyst
Valuation D

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 20.9x Better than 40%
Forward P/E 19.5x Better than 39%
Price / Sales 7.5x Better than 14%
P/E vs own 5-yr range 98th pctl Better than 5%
Growth A-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 18.0% Better than 80%
Net income CAGR (3Y) 22.4% Better than 74%
Free cash flow CAGR (3Y) 16.0% Better than 60%
Profitability A+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 87.9% Better than 95%
Operating margin 47.7% Better than 97%
Net margin 41.9% Better than 96%
Return on equity 19.7% Better than 78%
Return on invested capital 17.7% Better than 87%
Momentum A-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 8.1% Better than 88%
6-month return -2.4% Better than 51%
12-month return (ex latest month) 23.2% Better than 62%
Distance below 52-week high 9.7% Better than 84%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 6.6x Better than 90%
Debt to assets 4.1% Better than 82%
Interest coverage 88.9x Better than 93%
Free cash flow / net income 77.6% Better than 25%
Analyst View B-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 76.9% Better than 56%
Upside to average target 23.4% Better than 38%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -6.16%
1M +0.15%
3M +6.47%
6M -1.63%
YTD +13.85%
1Y +16.85%
3Y +142.25%
5Y +175.81%

Key statistics

Price & volume

Prev close
559.10
Open
561.20
Day range
551.77 - 563.12
Avg price
555.01
Volume
531.78K
Turnover
295.15M
Amplitude
2.03%
52-week range
455.63 - 614.23

Valuation

P/E
19.91
P/E (TTM)
20.94
P/B
3.76
EPS
27.86
Net profit
1.19B
Net assets
6.28B

Share structure

Market cap
23.63B
Float cap
21.60B
Shares out
42.59M
Float shares
38.94M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 62% of range
455.63 614.23

9.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-35.75M net over the window

Short interest

Shares short
1.84M
As of
2026-10-30

Frequently asked questions

What is the current stock price of United Therapeutics (UTHR)?

United Therapeutics last traded at 554.73. This page shows a periodic quote snapshot. Check the displayed quote time.

What is United Therapeutics's market cap?

About 23.63B.

What is the P/E ratio of United Therapeutics?

The trailing twelve-month P/E is 20.94, above its own 5-year average of 16.01 — toward the top of its historical range (98.25% percentile). See the Valuation tab for the full history.

Does United Therapeutics pay a dividend?

United Therapeutics does not currently pay a regular dividend.

Is United Therapeutics a buy according to analysts?

The consensus of 13 analysts is a Buy rating, with an average 12-month price target of 684.31, which implies 23.4% upside from the current price. This is not investment advice.

What is United Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates United Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.

United Therapeutics discussion 0 comments

Add a comment